Overview

A Multi-part, Double Blind Study to Assess Safety, Tolerability and Efficacy of Tropifexor (LJN452) in PBC Patients

Status:
Completed

Trial end date:
2018-08-02

Target enrollment:

Participant gender:

Summary

A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis

Phase:

Phase 2

Details

Lead Sponsor:

Novartis Pharmaceuticals